Read more

November 12, 2019
1 min read
Save

Pharmacological presbyopia options top AAO news

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In October, the American Academy of Ophthalmology held its annual meeting in San Francisco.

Healio/OSN was there to report on presentations and record videos with key opinion leaders.

Here are the top five most popular articles and videos from our coverage:

 

Pharmaceutical options for presbyopia on the horizon

Medical treatments for addressing presbyopia are on the horizon, with two approaches currently being studied. Read more.

 

Ziv -aflibercept may be safe, less expensive alternative to other anti-VEGF treatments

Ziv-aflibercept could be an effective and cost-reducing alternative to traditional anti-VEGF therapies in the treatment of neovascular age-related macular degeneration. Read more.

 

Long-term use of pentosan polysulfate sodium associated with vision-threatening maculopathy

Pentosan polysulfate sodium was approved by the FDA in 1996 for the treatment of interstitial cystitis, which currently affects more than 1 million U.S. adults. Read more.

 

VIDEO: Cataract surgery with KDB safe, effective at lowering IOP

Syril K. Dorairaj , MBBS, MD, of the Mayo Clinic in Jacksonville, Florida, discusses his study examining combined cataract surgery with Kahook Dual Blade (New World Medical) goniotomy for the treatment of glaucoma. Watch here.

 

Hypersonic vitrectomy has potential to replace guillotine vitrectomy cutters

Hypersonic vitrectomy devices, a method of vitreous removal in which ultrasonic power is used to actuate a vitrectomy probe, has the potential to replace current state-of-the-art guillotine vitrectomy cutters, but advances need to be made to improve the device’s ability to cut thick membranes more effectively. Read more.